FIELD: biotechnology.
SUBSTANCE: invention relates to a bispecific antibody having the substituting functional activity of blood coagulating factor VIII, a method of its production, as well as a pharmaceutical composition containing it. Also an isolated nucleic acid encoding the above antibody, as well as a vector and a cell containing it are disclosed.
EFFECT: invention is effective for use in the prevention and/or treatment of bleeding, a disease involving bleeding, or a disease caused by bleeding.
15 cl, 10 dwg, 8 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODY HAVING HIGH ACTIVITY, ALTERNATIVE FUNCTION OF COFACTOR FVIII | 2017 |
|
RU2821642C2 |
| LIGAND-BINDING MOLECULE WITH REGULATED LIGAND-BINDING ACTIVITY | 2017 |
|
RU2803067C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2800779C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| ANTIBODIES TO DENGUE VIRUS, POLYPEPTIDES CONTAINING FC-REGION OPTIONS AND THEIR APPLICATION METHODS | 2017 |
|
RU2758596C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC-REGION VARIANTS, AND THEIR APPLICATION METHODS | 2016 |
|
RU2789884C2 |
| ANTIBODIES TO DENGUE VIRUS WITH CROSS-REACTIVITY WITH ZIKA VIRUS | 2019 |
|
RU2811697C2 |
| ANTI-C5 ANTIBODIES AND METHODS FOR THEIR USE | 2017 |
|
RU2789788C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
